Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSTAR Bladder
NCT07414992Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, fianlimab in bladder urothelial carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Planned start Sep 2026; status: withdrawn.
02
Drugs
cemiplimabfianlimab
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT07414992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414992.